Stenhouse Mark 4
4 · Prometheus Biosciences, Inc. · Filed Dec 13, 2022
Insider Transaction Report
Form 4
Stenhouse Mark
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-12-09+34,085→ 34,085 totalExercise: $110.20Exp: 2032-12-08→ Common Stock (34,085 underlying) - Award
Common Stock
2022-12-09+9,811→ 26,442 total
Footnotes (3)
- [F1]Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award will vest and settle with respect to twenty-five percent (25%) of the total number of RSUs on December 9, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service with the Issuer through each vest date.
- [F2]Includes a total of 2,631 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
- [F3]25% of the shares subject to the option will vest on December 9, 2023, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.